Cell News and Research

RSS

Genetics Squared to change corporate name to Everist Genomics

Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

10 Jan 2011

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Advanced Pain Remedies, a subsidiary of Cato BioVentures, announces that a three million dollar grant has been received, to advance its lead development candidate, SP-SAP. Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases, has been awarded a $3 million grant from the National Cancer Institute (NCI).

10 Jan 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Omega-3 fatty acid may help protect against traumatic brain injury

Animal experiments suggest that taking the omega-3 fatty acid docosahexanoic acid (DHA) might offer a new way of protecting against traumatic brain injury (TBI), reports the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

10 Jan 2011

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

Researchers describe crucial initial steps taken by measles virus attachment proteins with receptors

Mayo Clinic researchers have shown that proteins on the surface of a cell twist a viral protein into position, allowing the virus to start infection and cause disease, all in a movement as graceful as a ballroom dance. The findings appear in the current online issue of Nature Structural & Molecular Biology.

10 Jan 2011

Slowing engines of mitochondria could extend life

In making your pro-longevity resolutions, like drinking more red wine and maintaining a vibrant social network, here's one you likely forgot: dialing down your mitochondria. It turns out that slowing the engines of these tiny cellular factories could extend your life-an observation relevant not only to aging research but to our understanding of how cells communicate with each another.

10 Jan 2011

Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C viruses in the journal Vaccine.

10 Jan 2011

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

Amsterdam Molecular Therapeutics, a leader in human gene therapy, announced today that it has entered into an agreement with Institut Pasteur, Paris, France, and a group of French research institutes (together the "Consortium") to support clinical development of a novel gene therapy to treat Sanfilippo B.

10 Jan 2011

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

Receptos grants license to OMJPI for GPCR crystal structure determination technology

Receptos, a biopharmaceutical company, today announces grant of license and technology transfer to Ortho-McNeil-Janssen Pharmaceuticals, for Receptos's breakthrough GPCR crystal structure determination technology.

10 Jan 2011

Scientists discover new anti-cancer mechanism

Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG prevents metastasis of tumor cells and enhances chemotherapy efficiency.

10 Jan 2011

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.

10 Jan 2011

U-M lab ranks No. 1 in protein structure and function prediction in scientific competition

The University of Michigan Health System took top honors in the Critical Assessment of Techniques for Protein Structure Prediction, a biennial scientific competition to test protein structure and function prediction methods developed by laboratories all over the world.

10 Jan 2011

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

9 Jan 2011

AFQ056 drug improves symptoms in Fragile X patients: Study

The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise according to a new study published in the January issue of Science Translational Medicine.

9 Jan 2011

Cell News and Research

Genetics Squared to change corporate name to Everist Genomics

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Omega-3 fatty acid may help protect against traumatic brain injury

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

LabCorp to market On-Q-ity's circulating tumor cell platform

Researchers describe crucial initial steps taken by measles virus attachment proteins with receptors

Slowing engines of mitochondria could extend life

Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

New mechanisms of resistance to chemotherapy among leukemia patients

Receptos grants license to OMJPI for GPCR crystal structure determination technology

Scientists discover new anti-cancer mechanism

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

U-M lab ranks No. 1 in protein structure and function prediction in scientific competition

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

AFQ056 drug improves symptoms in Fragile X patients: Study

How to optimize your cell line development eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics